rizatriptan ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 2393 144034-80-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • MK-0462
  • rizatriptan
  • risatriptan
  • rizatriptan benzoate
Rizatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Rizatriptan presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
  • Molecular weight: 269.35
  • Formula: C15H19N5
  • CLOGP: 1.45
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 49.74
  • ALOGS: -2.90
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 42 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 14 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.86 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 45 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.86 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 29, 1998 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Migraine 393.66 14.25 294 19227 103052 63366449
Neovascularisation 130.97 14.25 36 19485 1109 63468392
Drug ineffective for unapproved indication 109.94 14.25 88 19433 33975 63435526
Headache 102.05 14.25 424 19097 632817 62836684
Paradoxical drug reaction 92.26 14.25 38 19483 4114 63465387
Extrapyramidal disorder 55.39 14.25 40 19481 13244 63456257
Anuria 52.80 14.25 38 19483 12513 63456988
Swollen tongue 52.49 14.25 59 19462 34741 63434760
Contraindicated product administered 49.05 14.25 5 19516 217643 63251858
Gallbladder polyp 47.15 14.25 15 19506 772 63468729
Nausea 45.81 14.25 431 19090 854040 62615461
Death 44.96 14.25 30 19491 374351 63095150
Multiple sclerosis relapse 42.77 14.25 63 19458 48415 63421086
Dust allergy 40.46 14.25 13 19508 691 63468810
Serotonin syndrome 38.84 14.25 46 19475 28636 63440865
Hypermobility syndrome 38.47 14.25 13 19508 810 63468691
Medication overuse headache 38.33 14.25 13 19508 819 63468682
Anxiety 38.21 14.25 150 19371 217391 63252110
Pre-existing condition improved 37.08 14.25 26 19495 8218 63461283
Swelling face 35.21 14.25 67 19454 63408 63406093
Migraine with aura 34.93 14.25 17 19504 2723 63466778
Cholecystitis chronic 33.90 14.25 27 19494 10334 63459167
Product substitution issue 32.87 14.25 32 19489 15964 63453537
Depression 32.50 14.25 133 19388 196359 63273142
Dysphonia 32.48 14.25 55 19466 47559 63421942
Synovitis 31.85 14.25 9 19512 186909 63282592
Purpura senile 30.74 14.25 10 19511 553 63468948
Coronary artery dissection 30.25 14.25 11 19510 851 63468650
Anaphylactic reaction 29.79 14.25 64 19457 66036 63403465
Abdominal discomfort 29.63 14.25 33 19488 320852 63148649
Wound 29.46 14.25 7 19514 163256 63306245
Carotid artery dissection 26.79 14.25 7 19514 177 63469324
Alopecia 26.72 14.25 39 19482 337497 63132004
Arthropathy 26.59 14.25 20 19501 234772 63234729
Toxicity to various agents 25.60 14.25 23 19498 247227 63222274
Product physical issue 25.46 14.25 17 19504 4963 63464538
Suicidal ideation 25.37 14.25 58 19463 62363 63407138
Hepatic enzyme increased 24.54 14.25 16 19505 202312 63267189
Product dose omission issue 23.85 14.25 138 19383 234175 63235326
Feeling abnormal 23.39 14.25 99 19422 148293 63321208
Acute kidney injury 23.32 14.25 28 19493 263387 63206114
Abdominal pain 23.17 14.25 162 19359 293294 63176207
Pericarditis 23.04 14.25 6 19515 131573 63337928
Chest discomfort 22.76 14.25 80 19441 109889 63359612
Cholelithiasis 22.69 14.25 45 19476 43880 63425621
Tarsal tunnel syndrome 22.69 14.25 8 19513 566 63468935
Paraesthesia 22.67 14.25 102 19419 156864 63312637
Dizziness 22.44 14.25 216 19305 429709 63039792
Complex regional pain syndrome 22.41 14.25 12 19509 2345 63467156
Vestibular disorder 21.68 14.25 10 19511 1421 63468080
Sleep apnoea syndrome 21.68 14.25 35 19486 29098 63440403
Febrile neutropenia 21.52 14.25 5 19516 118444 63351057
Vertigo 21.48 14.25 53 19468 59834 63409667
Sinusitis 21.47 14.25 131 19390 226522 63242979
Muscle spasms 21.45 14.25 100 19421 156050 63313451
Surgery 21.28 14.25 39 19482 35873 63433628
Anaemia 21.22 14.25 36 19485 293394 63176107
Colitis ischaemic 21.21 14.25 21 19500 10687 63458814
Angioedema 21.10 14.25 46 19475 47919 63421582
Neutropenia 21 14.25 14 19507 174991 63294510
Stress 20.55 14.25 56 19465 67111 63402390
Vomiting 20.44 14.25 262 19259 559355 62910146
Joint swelling 20.38 14.25 44 19477 327622 63141879
Systemic lupus erythematosus 19.81 14.25 21 19500 208897 63260604
Allergy to animal 19.80 14.25 9 19512 1237 63468264
No adverse event 19.70 14.25 41 19480 41364 63428137
Atrioventricular septal defect 18.84 14.25 6 19515 310 63469191
Oesophagitis ulcerative 18.74 14.25 7 19514 584 63468917
Sensory level abnormal 18.35 14.25 5 19516 149 63469352
Somnolence 18.02 14.25 105 19416 178580 63290921
Ankylosing spondylitis 17.95 14.25 19 19502 10455 63459046
Atrial fibrillation 17.45 14.25 7 19514 116629 63352872
Platelet count decreased 17.32 14.25 7 19514 116115 63353386
Visual field defect 17.12 14.25 15 19506 6546 63462955
Vasospasm 17.02 14.25 7 19514 755 63468746
Dyspepsia 16.73 14.25 69 19452 102127 63367374
Palate injury 16.70 14.25 4 19517 70 63469431
Resorption bone increased 16.53 14.25 8 19513 1266 63468235
Weight decreased 16.40 14.25 143 19378 276655 63192846
Emotional distress 16.40 14.25 33 19488 32516 63436985
Therapeutic response unexpected 16.00 14.25 24 19497 18735 63450766
Completed suicide 15.74 14.25 13 19508 145660 63323841
Speech disorder 15.68 14.25 37 19484 40592 63428909
Broad ligament tear 15.43 14.25 3 19518 18 63469483
Wrong technique in product usage process 15.25 14.25 48 19473 62292 63407209
Gait inability 15.06 14.25 43 19478 52916 63416585
Hemiparaesthesia 15.06 14.25 4 19517 108 63469393
Burns third degree 15.02 14.25 5 19516 297 63469204
Vision blurred 15.00 14.25 62 19459 91862 63377639
Flushing 15.00 14.25 54 19467 75033 63394468
Rash 14.98 14.25 106 19415 560765 62908736
Sepsis 14.95 14.25 15 19506 153108 63316393
Pleural effusion 14.94 14.25 5 19516 93205 63376296
Nasal discharge discolouration 14.71 14.25 9 19512 2262 63467239
Palpitations 14.59 14.25 71 19450 112699 63356802
Facial pain 14.39 14.25 17 19504 10544 63458957

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nightmare 240.12 28.05 73 2429 14318 34940111
Sedation 212.97 28.05 73 2429 20933 34933496
Nephrolithiasis 193.91 28.05 75 2427 30258 34924171
Kounis syndrome 155.13 28.05 36 2466 2482 34951947
Hyperhidrosis 141.93 28.05 80 2422 75612 34878817
Product used for unknown indication 127.92 28.05 26 2476 957 34953472
Nausea 104.31 28.05 124 2378 339784 34614645
Drug ineffective 79.86 28.05 127 2375 456624 34497805
Migraine 79.75 28.05 34 2468 17444 34936985
Arteriospasm coronary 55.58 28.05 17 2485 3365 34951064
Product use in unapproved indication 53.38 28.05 53 2449 117446 34836983
Renal infarct 36.32 28.05 10 2492 1366 34953063
Venous angioma of brain 32.46 28.05 5 2497 34 34954395
Therapy partial responder 28.90 28.05 14 2488 9602 34944827

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Migraine 385.10 14.97 237 16797 87256 79640098
Neovascularisation 140.99 14.97 36 16998 1209 79726145
Nightmare 98.41 14.97 64 16970 25797 79701557
Drug ineffective for unapproved indication 98.29 14.97 84 16950 51154 79676200
Kounis syndrome 97.17 14.97 36 16998 4246 79723108
Headache 96.26 14.97 332 16702 653440 79073914
Nausea 93.38 14.97 427 16607 956769 78770585
Nephrolithiasis 87.51 14.97 80 16954 53211 79674143
Product used for unknown indication 83.55 14.97 25 17009 1519 79725835
Sedation 79.60 14.97 75 16959 51820 79675534
Paradoxical drug reaction 79.16 14.97 36 16998 7149 79720205
Drug ineffective 50.44 14.97 398 16636 1080515 78646839
Swollen tongue 49.58 14.97 53 16981 42517 79684837
Hypermobility syndrome 48.49 14.97 13 17021 529 79726825
Death 48.03 14.97 31 17003 566483 79160871
Arteriospasm coronary 47.90 14.97 25 17009 6691 79720663
Anuria 45.65 14.97 37 16997 20926 79706428
Hyperhidrosis 45.32 14.97 100 16934 151392 79575962
Dust allergy 42.67 14.97 15 17019 1521 79725833
Swelling face 41.81 14.97 63 16971 71149 79656205
Dysphonia 41.78 14.97 56 16978 56816 79670538
Extrapyramidal disorder 41.08 14.97 36 16998 22643 79704711
Gallbladder polyp 40.76 14.97 13 17021 977 79726377
Medication overuse headache 37.65 14.97 12 17022 900 79726454
Acute kidney injury 35.74 14.97 35 16999 519369 79207985
Migraine with aura 34.43 14.97 15 17019 2690 79724664
Cholecystitis chronic 34.01 14.97 23 17011 9883 79717471
Anaemia 31.76 14.97 29 17005 444986 79282368
Coronary artery dissection 31.13 14.97 11 17023 1133 79726221
Febrile neutropenia 30.76 14.97 6 17028 230993 79496361
Purpura senile 30.50 14.97 9 17025 521 79726833
Anxiety 30.28 14.97 119 16915 248393 79478961
Multiple sclerosis relapse 29.95 14.97 43 16991 46490 79680864
Colitis ischaemic 29.06 14.97 25 17009 15334 79712020
Depression 29.03 14.97 107 16927 216683 79510671
Dyspepsia 27.28 14.97 67 16967 108620 79618734
Neutropenia 26.81 14.97 14 17020 287696 79439658
Atrioventricular septal defect 26.71 14.97 6 17028 115 79727239
Product use in unapproved indication 26.64 14.97 115 16919 250244 79477110
Tarsal tunnel syndrome 26.09 14.97 8 17026 528 79726826
Paraesthesia 25.28 14.97 89 16945 176234 79551120
Product substitution issue 24.97 14.97 26 17008 20230 79707124
Carotid artery dissection 24.71 14.97 7 17027 350 79727004
Chest discomfort 24.56 14.97 75 16959 137969 79589385
Abdominal pain 24.15 14.97 154 16880 389415 79337939
Sinusitis 24.11 14.97 94 16940 195407 79531947
Vasospasm 23.78 14.97 9 17025 1125 79726229
Reversible cerebral vasoconstriction syndrome 23.59 14.97 12 17022 3045 79724309
Thrombocytopenia 23.14 14.97 14 17020 265245 79462109
Burns third degree 22.95 14.97 7 17027 454 79726900
Insomnia 22.63 14.97 108 16926 245062 79482292
Serotonin syndrome 22.49 14.97 37 16997 44990 79682364
Complex regional pain syndrome 21.73 14.97 10 17024 2038 79725316
Anaphylactic reaction 21.41 14.97 52 16982 83691 79643663
Atrial fibrillation 20.99 14.97 8 17026 197878 79529476
Pancytopenia 20.65 14.97 5 17029 165740 79561614
Platelet count decreased 20.43 14.97 8 17026 194656 79532698
Vomiting 20.17 14.97 224 16810 665604 79061750
Hypotension 19.94 14.97 40 16994 440277 79287077
Nasal discharge discolouration 19.76 14.97 10 17024 2511 79724843
Venous angioma of brain 19.71 14.97 4 17030 46 79727308
Sensory level abnormal 19.58 14.97 5 17029 168 79727186
Cholelithiasis 19.53 14.97 38 16996 52626 79674728
Ankylosing spondylitis 19.39 14.97 18 17016 12187 79715167
Toxicity to various agents 19.34 14.97 38 16996 421502 79305852
Malignant neoplasm progression 19.26 14.97 3 17031 135987 79591367
Angioedema 19.21 14.97 47 16987 75988 79651366
Dizziness 19.21 14.97 184 16850 526257 79201097
Renal impairment 19.19 14.97 5 17029 157778 79569576
Emotional distress 18.83 14.97 32 17002 39937 79687417
Injection site swelling 18.70 14.97 35 16999 47097 79680257
Sepsis 18.68 14.97 18 17016 269410 79457944
Flushing 18.63 14.97 51 16983 88217 79639137
Allergy to animal 18.38 14.97 8 17026 1431 79725923
Resorption bone increased 18.19 14.97 8 17026 1467 79725887
Palate injury 17.84 14.97 4 17030 76 79727278
Speech disorder 17.47 14.97 37 16997 54408 79672946
Pain 17.47 14.97 228 16806 703574 79023780
Therapy partial responder 17.39 14.97 20 17014 17377 79709977
Gastrointestinal haemorrhage 17.36 14.97 5 17029 147714 79579640
Contraindicated product administered 17.33 14.97 6 17028 157532 79569822
Vestibular disorder 17.11 14.97 9 17025 2446 79724908
Hypersensitivity 17.06 14.97 105 16929 262134 79465220
Throat tightness 16.81 14.97 25 17009 27882 79699472
Oesophagitis ulcerative 16.39 14.97 7 17027 1196 79726158
Renal infarct 16.34 14.97 9 17025 2682 79724672
Atheroembolism 16.18 14.97 5 17029 339 79727015
Device difficult to use 16.17 14.97 17 17017 13368 79713986
Wrong technique in product usage process 15.91 14.97 43 16991 73832 79653522
Asthma 15.87 14.97 64 16970 135031 79592323
Disease progression 15.70 14.97 10 17024 184352 79543002
Hepatic enzyme increased 15.42 14.97 10 17024 182600 79544754
Blood creatinine increased 15.26 14.97 7 17027 155050 79572304
Cardiac failure 15.23 14.97 7 17027 154835 79572519
Perfume sensitivity 14.98 14.97 6 17028 873 79726481

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02CC04 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:35941 serotonin agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Hemiplegic migraine contraindication 59292006
Prinzmetal angina contraindication 87343002
Chronic renal failure syndrome contraindication 90688005
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Myocardial ischemia contraindication 414795007 DOID:3393
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.75 acidic
pKa2 8.28 Basic
pKa3 3.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 6.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 7.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 5.10 CHEMBL
Cytochrome P450 2D6 Enzyme Ki 4.85 WOMBAT-PK
5-hydroxytryptamine receptor 1F GPCR AGONIST Ki 6.80 IUPHAR
5-hydroxytryptamine receptor 1E GPCR AGONIST Ki 6.80 IUPHAR
5-hydroxytryptamine receptor 1A GPCR Ki 6.85 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 5.10 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 5.20 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 7.30 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel IC50 5.40 CHEMBL

External reference:

IDSource
4021122 VUID
N0000148576 NUI
D00675 KEGG_DRUG
145202-66-0 SECONDARY_CAS_RN
4021122 VANDF
4021123 VANDF
C0297635 UMLSCUI
CHEBI:48273 CHEBI
CHEMBL905 ChEMBL_ID
CHEMBL1201032 ChEMBL_ID
DB00953 DRUGBANK_ID
C093622 MESH_SUPPLEMENTAL_RECORD_UI
5078 PUBCHEM_CID
51 IUPHAR_LIGAND_ID
7474 INN_ID
51086HBW8G UNII
237082 RXNORM
196735 MMSL
7484 MMSL
d04328 MMSL
007571 NDDF
007572 NDDF
108411001 SNOMEDCT_US
108412008 SNOMEDCT_US
363573000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MAXALT HUMAN PRESCRIPTION DRUG LABEL 1 0006-0266 TABLET 5 mg ORAL NDA 27 sections
MAXALT HUMAN PRESCRIPTION DRUG LABEL 1 0006-0267 TABLET 10 mg ORAL NDA 27 sections
MAXALT-MLT HUMAN PRESCRIPTION DRUG LABEL 1 0006-3800 TABLET, ORALLY DISINTEGRATING 5 mg ORAL NDA 27 sections
MAXALT-MLT HUMAN PRESCRIPTION DRUG LABEL 1 0006-3801 TABLET, ORALLY DISINTEGRATING 10 mg ORAL NDA 27 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7471 TABLET 5 mg ORAL ANDA 25 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7472 TABLET 10 mg ORAL ANDA 25 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 0378-1403 TABLET 5 mg ORAL ANDA 28 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 0378-1404 TABLET 10 mg ORAL ANDA 28 sections
MAXALT-MLT HUMAN PRESCRIPTION DRUG LABEL 1 16590-144 TABLET, ORALLY DISINTEGRATING 5 mg ORAL NDA 29 sections
MAXALT HUMAN PRESCRIPTION DRUG LABEL 1 16590-461 TABLET 10 mg ORAL NDA 29 sections
MAXALT HUMAN PRESCRIPTION DRUG LABEL 1 21695-956 TABLET 10 mg ORAL NDA 29 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 29300-268 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 23 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 29300-269 TABLET, ORALLY DISINTEGRATING 10 mg ORAL ANDA 23 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 29300-316 TABLET 5 mg ORAL ANDA 23 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 29300-316 TABLET 5 mg ORAL ANDA 23 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 29300-317 TABLET 10 mg ORAL ANDA 23 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 29300-317 TABLET 10 mg ORAL ANDA 23 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 31722-462 TABLET 5 mg ORAL ANDA 19 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 31722-463 TABLET 10 mg ORAL ANDA 19 sections
Rizatriptan Human Prescription Drug Label 1 33342-087 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Rizatriptan Human Prescription Drug Label 1 33342-087 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Rizatriptan Human Prescription Drug Label 1 33342-088 TABLET, FILM COATED 10 mg ORAL ANDA 25 sections
Rizatriptan Human Prescription Drug Label 1 33342-088 TABLET, FILM COATED 10 mg ORAL ANDA 25 sections
rizatriptan benzoate Human Prescription Drug Label 1 33342-093 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
rizatriptan benzoate Human Prescription Drug Label 1 33342-093 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
rizatriptan benzoate Human Prescription Drug Label 1 33342-093 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
rizatriptan benzoate Human Prescription Drug Label 1 33342-094 TABLET, ORALLY DISINTEGRATING 10 mg ORAL ANDA 26 sections
rizatriptan benzoate Human Prescription Drug Label 1 33342-094 TABLET, ORALLY DISINTEGRATING 10 mg ORAL ANDA 26 sections
rizatriptan benzoate Human Prescription Drug Label 1 33342-094 TABLET, ORALLY DISINTEGRATING 10 mg ORAL ANDA 26 sections
RIZATRIPTAN BENZOATE HUMAN PRESCRIPTION DRUG LABEL 1 43817-133 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 21 sections